08/08/2017 - 11:15am

As it named a new president, Diplomat reported Q2 results that showed increased revenue, but highlighted the margin pressure it’s seeing as the result of DIR fees. 

08/04/2017 - 2:38pm

Vyxeos combines two commonly used chemotherapies into a single formulation to treat patients with certain types of high-risk acute myeloid leukemia. 

08/04/2017 - 10:33am

The single-tablet hepatitis C regimen is now approved for use in patients with hepatitis C that are co-infected with HIV.

08/03/2017 - 4:47pm

The company’s pharmaceutical distribution services segment saw revenue of $37 billion, a 4.7% increase over the same quarter last year, with the AmerisourceBergen Drug Corp. seeing a revenue increase of 4.5% due largely to organic sales growth. 

08/03/2017 - 4:00pm
The FDA said that Mavyret is the first treatment of eight-week duration for all hepatitis C genotypes.
08/03/2017 - 3:19pm

The bill contains the reauthorizations of the Food and Drug Administration’s Prescription Drug, Biosimilar, and Generic Drug User Fee Acts.

08/03/2017 - 1:21pm

The drug received priority review and breakthrough therapy designations, as well as orphan drug designation for this indication.

08/03/2017 - 12:39pm

The Food and Drug Administration approved Nityt on Aug. 1 to treat the rare disease hereditary tyrosinemia Type 1, or HT-1, in combination with dietary restriction of tyrosine and phenylalanine.

08/02/2017 - 3:42pm
The new indication is for use in more than 600 people with cystic fibrosis ages 2 years and older who have one of five residual function mutations.